COVID-19 Vaccination Coverage in Italy: How Many Hospitalisations and Related Costs Could Have Been Saved If We Were All Vaccinated?

doi:10.3389/fpubh.2022.825416

. 2022 Mar 3:10:825416.

doi: 10.3389/fpubh.2022.825416. eCollection 2022.

COVID-19 Vaccination Coverage in Italy: How Many Hospitalisations and Related Costs Could Have Been Saved If We Were All Vaccinated?

Giulia Zamagni¹, Benedetta Armocida¹, Cristiana Abbafati², Luca Ronfani¹, Lorenzo Monasta¹

Affiliations

¹ Clinical Epidemiology and Public Health Research Unit, Institute for Maternal and Child Health-IRCCS "Burlo Garofolo", Trieste, Italy.
² Department of Juridical and Economic Studies, Sapienza University of Rome, Rome, Italy.

PMID: 35309223
PMCID: PMC8927714
DOI: 10.3389/fpubh.2022.825416

COVID-19 Vaccination Coverage in Italy: How Many Hospitalisations and Related Costs Could Have Been Saved If We Were All Vaccinated?

Giulia Zamagni et al. Front Public Health. 2022.

. 2022 Mar 3:10:825416.

doi: 10.3389/fpubh.2022.825416. eCollection 2022.

Authors

Giulia Zamagni¹, Benedetta Armocida¹, Cristiana Abbafati², Luca Ronfani¹, Lorenzo Monasta¹

Affiliations

¹ Clinical Epidemiology and Public Health Research Unit, Institute for Maternal and Child Health-IRCCS "Burlo Garofolo", Trieste, Italy.
² Department of Juridical and Economic Studies, Sapienza University of Rome, Rome, Italy.

PMID: 35309223
PMCID: PMC8927714
DOI: 10.3389/fpubh.2022.825416

No abstract available

Keywords: COVID-19; COVID-19 response; COVID-19 vaccination; Italy; public health.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Cited by

Strategic vaccination responses to Chikungunya outbreaks in Rome: Insights from a dynamic transmission model.
Sloof AC, Boer M, Vondeling GT, de Roo AM, Jaramillo JC, Postma MJ. Sloof AC, et al. PLoS Negl Trop Dis. 2024 Dec 9;18(12):e0012713. doi: 10.1371/journal.pntd.0012713. eCollection 2024 Dec. PLoS Negl Trop Dis. 2024. PMID: 39652620 Free PMC article.
A Serological Analysis of the Humoral Immune Responses of Anti-RBD IgG, Anti-S1 IgG, and Anti-S2 IgG Levels Correlated to Anti-N IgG Positivity and Negativity in Sicilian Healthcare Workers (HCWs) with Third Doses of the mRNA-Based SARS-CoV-2 Vaccine: A Retrospective Cohort Study.
Serra N, Andriolo M, Butera I, Mazzola G, Sergi CM, Fasciana TMA, Giammanco A, Gagliano MC, Cascio A, Di Carlo P. Serra N, et al. Vaccines (Basel). 2023 Jun 23;11(7):1136. doi: 10.3390/vaccines11071136. Vaccines (Basel). 2023. PMID: 37514952 Free PMC article.
COVID-19 recognition from chest X-ray images by combining deep learning with transfer learning.
Zhang CJ, Ruan LT, Ji LF, Feng LL, Tang FQ. Zhang CJ, et al. Digit Health. 2025 Feb 13;11:20552076251319667. doi: 10.1177/20552076251319667. eCollection 2025 Jan-Dec. Digit Health. 2025. PMID: 39949849 Free PMC article.
Integration of Cellular and Humoral Immune Responses as an Immunomonitoring Tool for SARS-CoV-2 Vaccination in Healthy and Fragile Subjects.
Brisotto G, Montico M, Turetta M, Zanussi S, Cozzi MR, Vettori R, Boschian Boschin R, Vinante L, Matrone F, Revelant A, Palazzari E, Innocente R, Fanetti G, Gerratana L, Garutti M, Lisanti C, Bolzonello S, Nicoloso MS, Steffan A, Muraro E. Brisotto G, et al. Viruses. 2023 May 30;15(6):1276. doi: 10.3390/v15061276. Viruses. 2023. PMID: 37376576 Free PMC article.

References

1. World Health Organization . WHO Coronavirus Disease (COVID-19) Dashboard. (2021). Available online at: https://covid19.who.int/ (accessed January 27, 2022).
1. World Health Organization . Regional Office for Europe. Statement—Update on COVID-19: Europe and Central Asia Again at the Epicenter of the Pandemic. Available online at: https://www.euro.who.int/en/media-centre/sections/statements/2021/statem... (accessed January 27, 2022).
1. Tartof SY, Slezak JM, Fischer H, Hong V, Ackerson BK, Ranasinghe ON, et al. . Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study. Lancet. (2021) 398:1407–16. 10.1016/S0140-6736(21)02183-8 - DOI - PMC - PubMed
1. Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, COVE Study Group. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med. (2020) 383:2603–15. 10.1056/NEJMoa2035389 - DOI - PMC - PubMed
1. Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S. C4591001 Clinical Trial Group. Safety and efficacy of the BNT162b2 mRNA covid-19 vaccine. N Engl J Med. (2020) 383:2603–15. 10.1056/NEJMoa2034577 - DOI - PMC - PubMed

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions

LinkOut - more resources

Full Text Sources
Medical
- MedlinePlus Health Information

[1] World Health Organization . WHO Coronavirus Disease (COVID-19) Dashboard. (2021). Available online at: https://covid19.who.int/ (accessed January 27, 2022).

[2] World Health Organization . WHO Coronavirus Disease (COVID-19) Dashboard. (2021). Available online at: https://covid19.who.int/ (accessed January 27, 2022).

[3] World Health Organization . Regional Office for Europe. Statement—Update on COVID-19: Europe and Central Asia Again at the Epicenter of the Pandemic. Available online at: https://www.euro.who.int/en/media-centre/sections/statements/2021/statem... (accessed January 27, 2022).

[4] World Health Organization . Regional Office for Europe. Statement—Update on COVID-19: Europe and Central Asia Again at the Epicenter of the Pandemic. Available online at: https://www.euro.who.int/en/media-centre/sections/statements/2021/statem... (accessed January 27, 2022).

[5] Tartof SY, Slezak JM, Fischer H, Hong V, Ackerson BK, Ranasinghe ON, et al. . Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study. Lancet. (2021) 398:1407–16. 10.1016/S0140-6736(21)02183-8 - DOI - PMC - PubMed

[6] Tartof SY, Slezak JM, Fischer H, Hong V, Ackerson BK, Ranasinghe ON, et al. . Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study. Lancet. (2021) 398:1407–16. 10.1016/S0140-6736(21)02183-8 - DOI - PMC - PubMed

[7] Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, COVE Study Group. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med. (2020) 383:2603–15. 10.1056/NEJMoa2035389 - DOI - PMC - PubMed

[8] Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, COVE Study Group. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med. (2020) 383:2603–15. 10.1056/NEJMoa2035389 - DOI - PMC - PubMed

[9] Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S. C4591001 Clinical Trial Group. Safety and efficacy of the BNT162b2 mRNA covid-19 vaccine. N Engl J Med. (2020) 383:2603–15. 10.1056/NEJMoa2034577 - DOI - PMC - PubMed

[10] Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S. C4591001 Clinical Trial Group. Safety and efficacy of the BNT162b2 mRNA covid-19 vaccine. N Engl J Med. (2020) 383:2603–15. 10.1056/NEJMoa2034577 - DOI - PMC - PubMed

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

COVID-19 Vaccination Coverage in Italy: How Many Hospitalisations and Related Costs Could Have Been Saved If We Were All Vaccinated?

Affiliations

COVID-19 Vaccination Coverage in Italy: How Many Hospitalisations and Related Costs Could Have Been Saved If We Were All Vaccinated?

Authors

Affiliations

Conflict of interest statement

Similar articles

Cited by

References

MeSH terms

Substances

LinkOut - more resources

Full Text Sources

Medical